Argentina Lung Cancer Therapeutics Market Report 2022 to 2030

Australia Lung Cancer Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Australia Lung Cancer Therapeutics Market will reach a value of $745 Mn from $358 Mn in 2022, growing at a CAGR of 9.6% during 2022-2030. The Lung Cancer Therapeutics Market in Australia is dominated by a few domestic pharmaceutical companies such as CSL Behring, Sirtex Medical, and Imugene. The Lung Cancer Therapeutics Market in Australia is segmented into different types of cancer and different therapy type. Some of the major factors affecting the Australian lung cancer therapeutics market are the prevalence of unhealthy lifestyles, demand for targeted therapies and the presence of highly efficient drugs.

ID: IN10AUPH041 CATEGORY: Pharmaceuticals GEOGRAPHY: Australia AUTHOR: Dr. Vishwa Modhia

Buy Now

Australia Lung Cancer Therapeutics Analysis Summary

By 2030, it is anticipated that the Australia Lung Cancer Therapeutics market will reach a value of $745 Mn from $358 Mn in 2022, growing at a CAGR of 9.6% during 2022-2030.

Australia is a high-income developed country in Oceania bordering the Indian Ocean and the Southern Pacific Ocean. In Australia, 14,529 new cases of lung cancer are expected to be diagnosed in 2022. The estimated percentage of new cancer cases diagnosed in Australia in 2022 is 9%. In 2018, lung cancer was the sixth most often diagnosed cancer in Australia. It is expected to be the fifth most often diagnosed cancer in 2022. Lung cancer was the leading cause of cancer death in Australia in 2020. Lung cancer accounts for 9.1 % of all new cancer diagnoses and is now the fourth most common malignancy in both men and women in Australia.

According to the latest WHO data published in 2020 Lung Cancers Deaths in Australia reached 8,769 or 6.43% of total deaths. The age-adjusted Death Rate is 18.97 per 100,000 of population ranks Australia 58^th in the world. Australia's government spends 10.7% of its GDP on healthcare.

Australia Lung Cancer Therapeutics Analysis

Market Dynamics

Market Growth Drivers

Rural and distant Australians have poorer health outcomes than their metropolitan counterparts, with greater rates of smoking, alcohol consumption, physical inactivity, and obesity. External beam radiotherapy accounts for more than 99 % of radiotherapy services invoiced to the MBS, with a linear accelerator accounting for about 97 % of these in Australia. The Royal Australasian College of Surgeons oversees all cardiothoracic surgery training in Australia. In Australia, there are roughly 160 trained cardiothoracic surgeons, 125 of whom are members of the Australian and New Zealand Society of Cardiac and Thoracic Surgeons. These aspects could boost Australia's Lung Cancer Therapeutics market.

Market Restraints

Because of the continent's low population density, radiotherapy provided in Australia has geographic challenges. Only about 20 physicians specialise in Thoracic Surgery, and they are largely concentrated in the densely populated Eastern states. Only six specialist thoracic surgery units exist in the country, with three of them located in Melbourne, Victoria. Australia's economy remains strongly dependent on Chinese spending. The disparities between Australia's federated states are vast. In Australia, effective tobacco control and comprehensive health care have lowered the burden of lung cancer. However, issues such as an ageing population, delivering equitable health care to rural and indigenous people, and smoking abolition remain. These factors may deter new entrants into the Australia Lung Cancer Therapeutics market.

Competitive Landscape

Key Players

CSL Behring: CSL Behring is an Australian biotechnology company that produces several drugs for the treatment of cancer, including lung cancer
Mayne Pharma: Mayne Pharma is an Australian pharmaceutical company that produces several drugs for the treatment of cancer, including lung cancer
Sirtex Medical: Sirtex Medical is an Australian biotechnology company that produces SIR-Spheres Y-90 resin microspheres, a treatment for inoperable liver cancer that has spread from the colon or rectum, including when it is accompanied by metastatic colorectal cancer of the liver.
Telix Pharmaceuticals: Telix Pharmaceuticals is an Australian biotechnology company that produces several drugs for the treatment of cancer, including lung cancer
Imugene
Mesoblast
Starpharma

Recent Notable Updates

May 2022: The Lung Foundation is advocating for a $60 million pilot screening programme that would provide low-dose CT scans to those over the age of 55 who have a history of smoking. Over the next decade, it is expected to save 10,000 Australians.

Healthcare Policies and Reimbursement Scenarios

Lung cancer therapeutics in Australia are managed and reimbursed by several entities, including the Therapeutic Goods Administration (TGA), the Pharmaceutical Benefits Scheme (PBS), and the Australian healthcare system. The TGA oversees controlling and approving lung cancer therapies in Australia. The PBS oversees reimbursing lung cancer treatments approved by the Pharmaceutical Benefits Advisory Committee (PBAC). Also, some lung cancer medicines may be available through PBS special programmes, such as the Life-Saving Drugs Program, which funds lung cancer treatments that are not regularly offered.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Lung Cancer Therapeutics Segmentation

By Type (Revenue, USD Billion):

Small Cell Lung Cancer
Non-small Cell Lung Cancer
Lung Carcinoid Tumor

By Therapy (Revenue, USD Billion):

Radiation Therapy
Targeted Therapy
Immunotherapy
Chemotherapy
Others

By Type of Molecule (Revenue, USD Billion):

Small Molecules
Biologics

By Drug Class (Revenue, USD Billion):

Alkylating Agents
Antimetabolites
Multikinase Inhibitors
Mitotic Inhibitors
EGFR Inhibitors
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.